For the Inventor, By the Inventor

Enter assignee name

Ness Ziona, Israel

Mapi Pharma Ltd.

USPTO Granted Patents = 35

% Expired Patents = 17.1

EPO Patents = 18

Forward Citations = 60

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Ehud Marom (34 out of 36 patents)

Shai Rubnov (26 out of 26 patents)

Nadav Bleich Kimelman (10 out of 10 patents)

4. Michael Mizhiritskii (9 out of 10 patents)

5. Uri Danon (3 out of 3 patents)

6. Anna Gopin (3 out of 3 patents)

7. Galina Zats (3 out of 3 patents)

8. Frida Grynspan (2 out of 3 patents)

9. Yoram Sela (2 out of 13 patents)

10. Laura Popper (2 out of 2 patents)

11. Susanna Tchilibon (1 out of 6 patents)

35 patents: Sort by Forward Citations

1. 12514908 - Semaglutide depot systems and use thereof (2026-01-06),

2. 12370233 - Depot systems comprising glatiramer acetate (2025-07-29),

3. 12343371 - Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate (2025-07-01),

4. 12251380 - Depot systems comprising cariprazine or salts thereof (2025-03-18),

5. RE50301 - Depot systems comprising glatiramer or pharmacologically acceptable salt thereof (2025-02-18),

6. 12161688 - Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells (2024-12-10),

7. 12097292 - Process for preparing microparticles containing glatiramer acetate (2024-09-24),

8. 11931357 - Depot systems comprising Cariprazine or salts thereof (2024-03-19),

9. 11865213 - Semaglutide depot systems and use thereof (2024-01-09),

10. RE49251 - Depot systems comprising glatiramer or pharmacologically acceptable salt thereof (2022-10-17),

11. 11471421 - Process for preparing microparticles containing glatiramer acetate (2022-10-18),

12. 11413311 - Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells (2022-08-16),

13. 11167003 - Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems (2021-11-09),

14. 11026908 - Extended release dosage forms of pregabalin (2021-06-08),

15. 10493122 - Sublingual delivery of glatiramer acetate (2019-12-03),

MAPI Pharma Ltd. is a pharmaceutical company specializing in the development and commercialization of novel drug delivery systems. With a focus on improving patient outcomes and convenience, MAPI Pharma offers innovative solutions for various therapeutic areas. Our dedicated team of experts is committed to driving scientific advancements and delivering high-quality medicines to patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

35 Patents

#3 in Ness Ziona

#156 in Israel

#19,126 in the World

Ness Ziona, Israel

Mapi Pharma Ltd.

Forward Citations = 60

11 inventors:

Ehud Marom (34 out of 36 patents)

Shai Rubnov (26 out of 26 patents)

Nadav Bleich Kimelman (10 out of 10 patents)

4. Michael Mizhiritskii (9 out of 10 patents)

5. Uri Danon (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…